Table 3.
Comparative results of mean difference in coagulation profile among individuals using different lipid-lowering drugs
| Adjusted mean differencea (95%CI) | Adjusted mean difference a (95% CI) | Adjusted mean difference a (95% CI) | |
|---|---|---|---|
| Fibrinogen, mg/dL | |||
| Fibrate/Niacin users | – | Reference | Reference |
| Other statin users | Reference | – | 18.6 (− 11.0 to 48.4) |
| Rosuvastatin users | 1.5 (−12.1 to 15.3) | – | 20.7 (− 6.2 to 47.6) |
| All statin users | – | 19.1(− 10.0 to 48.2) | – |
| Factor VIII, IU/dL | |||
| Fibrate/Niacin users | – | Reference | Reference |
| Other statin users | Reference | – | − 15.5 (− 31.5 to 0.5) |
| Rosuvastatin users | −2.6 (− 10.1 to 4.7) | – | − 17.6 (− 33.8 to −1.3) |
| All statin users | – | − 15.8 (− 31.6 to 0.003) | – |
| Factor IX, IU/dL | |||
| Fibrate/Niacin users | – | Reference | Reference |
| Other statin users | Reference | – | − 11.0 (− 22.7 to 0.7) |
| Rosuvastatin users | −2.3 (− 7.9 to 3.1) | – | − 14.9 (− 29.7 to − 0.08) |
| All statin users | – | −11.3 (− 23.2 to 0.4) | – |
| Factor XI, IU/dL | |||
| Fibrate/Niacin users | – | Reference | Reference |
| Other statin users | Reference | – | −18.3 (− 27.4 to − 9.2) |
| Rosuvastatin users | 0.3 (−3.8 to 4.5) | – | −17.6 (− 27.4 to − 7.7) |
| All statin users | – | − 18.3 (− 27.3 to − 9.4) | – |
CI confidence interval
aadjusted for age, sex, body mass index, hypertension, smoking, diabetes, cardiovascular diseases